Femasys stock.

Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.

Femasys stock. Things To Know About Femasys stock.

Femasys Inc. (NASDAQ: FEMY) shares fell lower on Wednesday, a pullback from Tuesday's surge in price following the announcement that the company received FDA 510(k) clearance for FemaSeed, Femasys (FEMY) For the next stock on our list, we’ll take a look at another company in the health care universe. Femasys occupies a unique niche, whose nature is implied in the name.Femasys Inc. (NASDAQ: FEMY) shares fell lower on Wednesday, a pullback from Tuesday's surge in price following the announcement that the company received FDA 510(k) clearance for FemaSeed, Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.

Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late ...Dec 31, 2022 · Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors Chuck Padala LifeSci Advisors, LLC +1-917-741-7792 [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact ... View Our Latest Stock Analysis on FEMY. Femasys Price Performance. FEMY opened at $0.96 on Monday. The business has a fifty day moving average of $1.25 and a 200 day moving average of $0.81. Femasys has a 52-week low of $0.25 and a 52-week high of $4.75. The company has a quick ratio of 8.28, a current ratio of 4.68 and a …

LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions ...Oct 26, 2023 · Oct. 26, 2023, 08:30 AM. – Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys ...

Oct 11, 2023 · Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ... Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ... Nov 29, 2023 · Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testing The stock is up ~205% in after-hours trading on Monday. Femasys (FEMY) says that FeedSeed is "less invasive and more affordable than assisted reproduction procedures, such as in vitro ...Latest Femasys News: View FEMY news and discuss market sentiment with the investor community on Public.com.

Nov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the ...

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …

Find the latest SEC Filings data for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.Historical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.FEMASYS INC. EMPLOYEE STOCK PURCHASE PLAN 1. SECTION 1. PURPOSE OF THE PLAN. The Femasys Inc. Employee Stock Purchase Plan (the “Plan”) is intended to provide Eligible Employees (as defined below) the opportunity to increase their proprietary interest in Femasys Inc. (the “Company”) by conveniently purchasing shares of the …Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock This prospectus is not an offer to sell.Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

Femasys story: Human Papillomavirus Testing Pap Test Market By Test Type,Application,Business Growth and Is Grow at a EIN News and other headlines for Femasys StockNov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ... The stock is up ~205% in after-hours trading on Monday. Femasys (FEMY) says that FeedSeed is "less invasive and more affordable than assisted reproduction procedures, such as in vitro ...Femasys Inc. FEMY shares are up more than 14% on Monday and have gained more than 900% over the last five days. Here's a look at what's going on:. What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday.. Femasys also announced last …Femasys Inc. 2021 Employee Stock Purchase Plan, incorporated by reference to Exhibit 10.4 of the registrant’s Form S-1 filed May 14, 2021 10.3 Amended and Restated Employment Agreement, by and between Femasys Inc. and Kathy Lee-Sepsick, incorporated by reference to Exhibit 10.6 of the registrant’s Form S-1/A filed June 14, 2021Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Femasys Inc have a median target of 8.50, with a high estimate of 12.00 and a low estimate of 5.00. The median estimate ...Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility.

Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.

Get Femasys Inc (FEMY) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. FEMY, a biomedical company focused on meeting significant unmet needs for women worldwide with a broad …WebFemasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock This prospectus is not an offer to sell.Dec 1, 2023 · Femasys (FEMY) stock price is up 1,250% but there are 2 key risks. The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar... 7 weeks ago - Invezz. Jul 27, 2023 · InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Shares of biomedical firm Femasys (NASDAQ:FEMY) more than doubled on Thursday.This followed an important intellectual property (IP ... FEMY Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $10.67 with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 620.95% change from the last price of $1.48.

Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.

Dec 1, 2023 · Femasys (FEMY) stock price is up 1,250% but there are 2 key risks. The remarkable Femasys (NASDAQ: FEMY) stock price comeback continued on Monday as demand for the shares continued. The shares surged by more than 45% on Friday and gained by another 15% in the pre-mar... 7 weeks ago - Invezz.

Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Get Femasys Inc (FEMY) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy.Nov 30, 2023 · According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy. Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products.Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ...Nov 24, 2023 · Complete Femasys Inc. stock information by Barron's. View real-time FEMY stock price and news, along with industry-best analysis. Read Full Company Summary for FEMY here. View Femasys Inc FEMY investment & stock information. Get the latest Femasys Inc FEMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Find real-time FEMY - Femasys Inc stock quotes, company profile, news and forecasts from CNN Business. Nov. 30, 2023 5:40 PM ET Femasys Inc. (FEMY) By: Tiyashi Datta, SA News Editor. Femasys ( NASDAQ: FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an ...Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.Instagram:https://instagram. best stock alert appbbkcflemonade term life insurancenyse hlly Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen. refineries in the united statesrev group inc Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 13.36% for FEMY.At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. smart move reviews Femasys Inc. is a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally ...(RTTNews) - Femasys Inc. (FEMY) announced on Monday that the FDA has granted 510(k) Clearance for FemaSeed, an option for intratubal artificial insemination that enhances the natural fertilization ...Historical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.